Li et al. [83] conducted a phase I clinical trial to evaluate the feasibility, safety, and effectiveness of personalized Neoantigen (NeoAg) peptide vaccination (PPV) in patients with stage III/IV non-small cell lung cancer (NSCLC) and EGFR mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.